So AMRN sees no benefit in even doing a fairly short ...say 3 yr revascularisation trial like the following ..especially in light of the EU patent extension.
Based on the graphs Laurent / Capt have posted , there should be very clear separation in event lines by 3 yrs , in revasc rates following a PCI between SOC and SOC plus Vascepa . There probably a lot of RWE data already on this waiting to be analyzed .